Boston Scientific reports Q3 adjusted EPS 63c, consensus 59c

Reports Q3 revenue $4.21B, consensus $4.04B. “Our sustained high performance is a testament to the strength of our talented global team, differentiated portfolio and category leadership strategy,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific (BSX). “We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.”